Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart attack patients

- PMLiVE

AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer

Improved overall survival when compared to chemotherapy

- PMLiVE

AZ says Brilinta hits the mark in new stroke trial

Drug met primary endpoint in phase 3 THALES trial

AstraZeneca AZ

AZ’s Imfinzi scores orphan drug status in liver cancer

Company is looking to gain approval in the first-line advanced setting

- PMLiVE

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

Initial guidance says drug is too costly but encourages further data

- PMLiVE

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

Cost-effectiveness watchdog issues a round of draft and final guidance

- PMLiVE

NICE rejects Akcea’s rare inherited disorder drug Waylivra

Draft guidance deems drug too costly for NHS use

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

- PMLiVE

AZ, Merck win FDA approval for Lynparza in pancreatic cancer

New treatment option for subset of patients with BRCA-mutations

- PMLiVE

AZ, Merck’s Lynparza narrowly scores FDA approval for pancreatic cancer

Committee voted seven to five in favour of PARP inhibitor

- PMLiVE

AZ, Daiichi Sankyo strengthen case for HER2 candidate

Will rival Roche's HER2 franchise if approved

- PMLiVE

AstraZeneca’s Calquence impresses in previously untreated CLL

Takes the fight to AbbVie/J&J’s Imbruvica

- PMLiVE

Lynparza cleared for first-line ovarian cancer use in China

Continues to cement lead in PARP inhibitor category

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links